1. Home
  2. COHR vs UTHR Comparison

COHR vs UTHR Comparison

Compare COHR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coherent Corp.

COHR

Coherent Corp.

HOLD

Current Price

$182.50

Market Cap

21.9B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHR
UTHR
Founded
1971
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.9B
20.3B
IPO Year
1987
1999

Fundamental Metrics

Financial Performance
Metric
COHR
UTHR
Price
$182.50
$488.92
Analyst Decision
Strong Buy
Buy
Analyst Count
14
12
Target Price
$144.54
$495.08
AVG Volume (30 Days)
5.0M
424.3K
Earning Date
11-05-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.08
EPS
0.76
26.38
Revenue
$6,043,358,000.00
$3,128,400,000.00
Revenue This Year
$17.38
$13.64
Revenue Next Year
$13.50
$5.78
P/E Ratio
$238.87
$18.55
Revenue Growth
20.80
13.50
52 Week Low
$45.58
$266.98
52 Week High
$188.36
$492.62

Technical Indicators

Market Signals
Indicator
COHR
UTHR
Relative Strength Index (RSI) 72.40 68.10
Support Level $158.21 $470.13
Resistance Level $172.58 $492.62
Average True Range (ATR) 10.66 10.72
MACD 2.57 -0.53
Stochastic Oscillator 88.52 89.55

Price Performance

Historical Comparison
COHR
UTHR

About COHR Coherent Corp.

Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: